Bluejay Diagnostics (BJDX) Long-Term Debt Issuances (2021)

Bluejay Diagnostics (BJDX) reported Long-Term Debt Issuances of -$4.2 million for Q4 2021, down 380.69% sequentially from $1.5 million in Q3 2021.

Bluejay Diagnostics (BJDX) Long-Term Debt Issuances (2021) Analysis & Trends

Bluejay Diagnostics (BJDX) has 1 years of Long-Term Debt Issuances data on file, last reported at -$4.2 million in Q4 2021.

For the quarter ending Q4 2021, Long-Term Debt Issuances changed N/A year-over-year to -$4.2 million; the trailing twelve-month figure through Dec 2024 stood at -$2.7 million (changed N/A YoY), and the FY2024 full-year result was $2.0 million, changed N/A from the prior year.
Long-Term Debt Issuances fell to -$4.2 million in Q4 2021, from $1.5 million in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $2.7 million in Q2 2021 to a low of -$4.2 million in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	19.86 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	-
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	-
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	-
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	-
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	11.71 Mn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	1.15 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	-
10	Bluejay Diagnostics	2,754.24	2,754.24	-	-

Download Data